Author Archives: Marta Figueiredo PhD

#AANAM – Study Examines Seronegative Characteristics

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read stories from the conference. Myasthenia gravis (MG) patients who test negative for the presence of the most common MG self-reactive antibodies (autoantibodies) more…

Big Early Effects in Immunosuppressive Therapy Predict Better Outcomes

Greater reductions in the levels of antibodies against the acetylcholine receptor (AChR) within the first three months after immunosuppressive treatment in people with myasthenia gravis (MG) are associated with better one-year post-therapy outcomes, a study shows. These findings suggest that measuring anti-AChR antibodies shortly after the start of such therapy…

Disease Crisis Linked to Distinct Pro-inflammatory Immune Changes

Myasthenia gravis (MG) crisis, the disease’s most severe state, is associated with pronounced pro-inflammatory cellular and molecular changes, a recent study shows. Notably, several pro-inflammatory immune cells and molecules were found to be associated with symptom severity, adding to previous data showing a link between certain pro-inflammatory cells…